Keywords
Children
Adolescents
Insulin infusion system
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate the impact of continuous insulin infusion systems on glycemic control in pediatric patients with T1DM. Methods: A systematic review was conducted and registered in PROSPERO (CRD420261358186) to ensure methodological transparency. The search strategy was developed using DeCS/MeSH descriptors. Searches were performed in PubMed, CAPES Portal, and Cochrane databases. Studies published in the last five years and involving patients diagnosed with T1DM up to 18 years of age were included. A total of 19 studies were included in this review. Results: Studies involving children aged 1 to 7 years demonstrated a significant increase in TIR and reduction in HbA1c, without an increase in hypoglycemia. In children aged 6 to 12 years, a reduction in time spent in hypoglycemia and improvement in metabolic control were observed. Very young children showed an absolute increase of approximately 8–9 percentage points in TIR. Advanced hybrid systems maintained benefits throughout the intervention period, with reduced hypoglycemia and lower exposure to hyperglycemia. Studies also reported improved treatment satisfaction, reduced fear of hypoglycemia, and decreased diabetes management burden. Conclusions: Automated continuous insulin infusion systems provide relevant clinical benefits in glycemic control among children and adolescents with T1DM, promoting both metabolic and psychosocial improvements.
References
AMERICAN DIABETES ASSOCIATION PROFESSIONAL PRACTICE COMMITTEE FOR DIABETES. 7. Diabetes Technology: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Supplement_1):S150-S165.
BOMBACI B, et al. Impact of automated insulin delivery systems in children and adolescents with type 1 diabetes previously treated with multiple daily injections: A single-center real-world study. Medicina, 2025; 61(9): 1602.
BOMBACI B, et al. One-year real-world study on comparison among different continuous subcutaneous insulin infusion devices for the management of pediatric patients with type 1 diabetes: The supremacy of hybrid closed-loop systems. International Journal of Environmental Research and Public Health, 2022; 19(16): 10293.
BOMBACI B, et al. Real-world performance of first- versus second-generation automated insulin delivery systems on a pediatric population with type 1 diabetes: A one-year observational study. Journal of Diabetes Science and Technology, 2025; 19(1): 98–104.
DESALVO DJ, et al. Glycemic outcomes persist for up to 2 years in very young children with the Omnipod® 5 automated insulin delivery system. Diabetes Technology & Therapeutics, 2024; 26(6): 383–393.
DICKINSON I, et al. Technology usage and glycaemic outcomes in a single tertiary centre with an ethnically diverse and socioeconomically deprived cohort of children with type 1 diabetes mellitus. Frontiers in Clinical Diabetes and Healthcare, 2025; 5: 1417287.
DOVC K, et al. Consistent efficacy and safety of automated insulin delivery in children aged 2–6 years: Results from the LENNY trial continuation phase. Diabetes Research and Clinical Practice, 2025; 230: 112934.
FORLENZA GP, et al. Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial. Pediatric Diabetes, 2022; 23(3): 324–329.
HU S, et al. Clinical outcome and cost-effectiveness analysis of CSII versus MDI in children and adolescent with type 1 diabetes mellitus in a public health care system of China. Frontiers in Endocrinology, 2021; 12: 604028.
KANAPKA LG, et al. Extended use of the Control-IQ closed-loop control system in children with type 1 diabetes. Diabetes Care, 2021; 44(2): 473–478.
KARIYAWASAM D, et al. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: A randomised, controlled, cross-over, non-inferiority trial. The Lancet Digital Health, 2022; 4(3): e158–e168.
MESSER LH, et al. Positive impact of the bionic pancreas on diabetes control in youth 6–17 years old with type 1 diabetes: A multicenter randomized trial. Diabetes Technology & Therapeutics, 2022; 24(10): 712–725.
PETROVSKI G, et al. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: Drivers to successful outcomes. Acta Diabetologica, 2021; 58(2): 207–213.
PIHOKER C, et al. Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. Diabetes Technology & Therapeutics, 2023; 25(11): 755–764.
RAPINI N, et al. Efficacy and safety of advanced hybrid closed-loop systems in children with type 1 diabetes younger than 6 years. Frontiers in Endocrinology, 2024; 15: 1382920.
SHERR JL, et al. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: A single-arm multicenter clinical trial. Diabetes Care, 2022; 45(8): 1907–1910.
WADWA RP, et al. Trial of hybrid closed-loop control in young children with type 1 diabetes. New England Journal of Medicine, 2023; 388(11): 991–1001.
WARE J, et al. Randomized trial of closed-loop control in very young children with type 1 diabetes. New England Journal of Medicine, 2022; 386(3): 209–219.
WARE J, et al. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: A multicentre 6-month randomised controlled trial. The Lancet Digital Health, 2022; 4(4): e245–e255.
WARE J, et al. Effect of 48 months of closed-loop insulin delivery on residual C-peptide secretion and glycemic control in newly diagnosed youth with type 1 diabetes: A randomized trial. Diabetes Care, 2024; 47(8): 1441–1448.
WARE J, et al. Eighteen-month hybrid closed-loop use in very young children with type 1 diabetes: A single-arm multicenter trial. Diabetes Care, 2024; 47(12): 2189–2195.